Physician profile
Daniel Lau
NPI 1225587090
$6,288.58
in general payments reported to CMS, 2019-2025
23 companies · $554 in 2025
The $554 reported for 2025 was more than what 77% of Psychiatric/Mental Health (Registered Nurse) providers received nationally (typical 2025 total: $137).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,326 · 2022: $1,678 · 2023: $2,071 · 2024: $660 · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,261 · Education: $23.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,261.14 |
| Education | $23.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,139.33 | 2021-2023 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $1,012.40 | 2021-2024 | |
| Indivior INC. | $831.21 | 2021-2025 | Sublocade, Perseris |
| Otsuka America Pharmaceutical, INC. | $669.96 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $428.71 | 2021-2024 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $353.39 | 2022-2024 | Austedo Xr, Austedo, Uzedy |
| Axsome Therapeutics, INC. | $314.66 | 2022-2023 | Auvelity |
| Janssen Pharmaceuticals, INC | $238.89 | 2022-2023 | Invega Trinza, Spravato, Invega Sustenna |
| Braeburn INC. | $234.02 | 2024-2025 | Brixadi |
| Sunovion Pharmaceuticals INC. | $153.09 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $152.18 | 2021-2022 | |
| Lundbeck LLC | $151.02 | 2021-2023 | Rexulti |
| Avanir Pharmaceuticals, INC. | $111.59 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $104.18 | 2023 | |
| Eisai INC. | $103.09 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $78.43 | 2022-2025 | Fanapt |
| Almatica Pharma LLC | $52.47 | 2023 | Sertraline Hcl, Loreev Xr |
| Idorsia Pharmaceuticals US INC | $46.67 | 2023 | Quviviq |
| Bausch Health US, LLC | $32.94 | 2022-2023 | Aplenzin, Wellbutrin |
| Ironshore Pharmaceuticals INC. | $23.65 | 2023 | Jornay Pm |
| Corium, LLC | $22.06 | 2022-2023 | Azstarys |
| Allergan, INC. | $18.53 | 2021 | |
| Noven Therapeutics, LLC | $16.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.